AI Terminal
Xbrane Biopharma
Board/Management Information • Dec 20, 2023
3128_rns_2023-12-20_51c223f5-c4b8-41cb-a935-50d4ef662e59.pdf
Board/Management Information
Open in ViewerOpens in native device viewer
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES
In accordance with the principles of the Nomination Committee of Xbrane Biopharma AB ("Company" or "Xbrane"), adopted at the Annual General Meeting ("AGM") on May 4th, 2023, the nomination committee, shall consist of three members, nominated by the Company's three largest shareholders per 30 September 2023. One shareholder has ceased to be one of Company's three largest shareholders, why the member has resigned from the nomination committee and a new member has been appointed.
The nomination committee, which has been appointed for the time until a new nomination committee has been appointed, consists of three members, nominated by the Company's three largest shareholders with respect to voting power as per 30 September 2023. If a shareholder who has appointed a member of the nomination committee during the year ceases to be one of the Company's three largest shareholders, the member appointed by such shareholder shall resign from the nomination committee. Instead, a new shareholder among the three largest shareholders shall be entitled to independently and in its sole discretion appoint a member of the nomination committee.
Based on the above, the Nomination Committee for the AGM in 2024 consists of the following;
- Saeid Esmaeilzadeh, appointed by Systematic Group AB, the Company´s largest shareholder,
- Bengt Göran Westman, the Company´s second largest shareholder
- Oscar Bergman appointed by Swedbank Robur Fonder, the Company´s third largest shareholder
- Anders Tullgren, Chairman of the Company co-opted member
In addition, Saeid Esmaeilzadeh, has been appointed Chairman of the Nomination Committee.
The task of the Nomination Committee is prior to AGM prepare and submit proposals regarding the Chairman of the AGM, candidates for the post of chairman and other directors of the board, fees, and other remuneration for board work to each director, fees to members of committees within the board, election and remuneration of the Company auditor and principles for the nomination committee. The Nomination Committee's proposal will be presented in the notice to the AGM 2024 and on the Company's website, www.xbrane.com.
Shareholders may submit proposals to the Nomination Committee for the AGM on May 2nd, 2024, until January 22, 2024. The proposals can be sent to the following address: Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Retzius väg 8, 171 65 Solna, Sweden, or via email: [email protected].
The Annual General Meeting will be held in Stockholm May 2nd, 2024.
Contacts
Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]
Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 27 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com